Bempedoic acid is named as an intervention in 3 current clinical trials in our UK, USA and India registers. 2 are recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (1). The most-studied condition is Hypercholesterolemia.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Bempedoic Acid Pregnancy Surveillance Program
NCT05103254 · ClinicalTrials.gov ↗ · Pregnancy, Hyperlipidemias
|
Observational | Recruiting | Esperion Therapeutics, Inc. | USA |
|
Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
NCT06035874 · ClinicalTrials.gov ↗ · Type 2 Diabetes, Non Alcholic Fatty Liver Disease
|
Not applicable | Recruiting | Medanta, The Medicity, India | India |
|
Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
NCT04579367 · Hypercholesterolemia, Mixed Dyslipidemia
|
Observational | Active, closed | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | UK |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 1 |
| Esperion Therapeutics, Inc. | 1 |
| Medanta, The Medicity, India | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 1 | 0 |
| Clinical trials in USA | 1 | 1 |
| Clinical trials in India | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our UK, USA and India registers name Bempedoic acid as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in USA and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (1), Esperion Therapeutics, Inc (1) and Medanta, The Medicity, India (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Bempedoic acid works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Bempedoic acid works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Bempedoic acid (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.